Nirmatrelvir and ritonavir combination for treating mild-to-moderate COVID-19

Published on 25 Oct 2024
Last Updated on 25 Oct 2024

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Nirmatrelvir 150 mg tablet and ritonavir 100 mg tablet combination for treating mild-to-moderate Coronavirus Disease 2019 (COVID-19) in patients aged 18 years or older who are immunocompromised.

Funding status

Nirmatrelvir 150 mg tablet and ritonavir 100 mg tablet combination is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2024.

Nirmatrelvir and ritonavir combination should be used in line with the additional clinical criteria listed in the Annex.

Nirmatrelvir and ritonavir combination for treating mild-to-moderate COVID-19 (25 Oct 2024) [PDF, 144 KB]

PES Nirmatrelvir and ritonavir combination for treating mild-to-moderate COVID-19 (25 Oct 2024) [PDF, 54 KB]